UNSPSC 51314203: Flutropium bromide

This classification denotes a mast cell stabilizer with the molecular formula C24H29FNO3.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3V6HB0M57, chemically known as 1-alpha-h,5-alpha-h-tropanium, 8-(2-fluoroethyl)-3-alpha-hydroxy-, bromide, benzilate, (8r)- but more generally known as flutropium bromide, which bears US NIH Compound Identifier 71962. European Medicines Agency schedules Flutropium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07767MIG.

UNSPSC 51314203 Flutropium bromide is a Commodity code that in practice covers pharmaceutical procurement by state and local health agencies, though recent solicitations under this code show minimal activity directly aligned with the nominal product scope. State and local governments are instead using this or related pharmaceutical codes to solicit naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through a mix of issuing bodies including county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work involves establishing supply contracts with manufacturers and authorized wholesalers, meeting FDA compliance and Good Manufacturing Practice (cGMP) certification requirements, managing pricing structures across multiple distribution channels, and delivering products to community health facilities or participating government agencies. Contracts typically include provisions for workers' compensation and commercial general liability insurance, E-Verify compliance, and performance penalties for reporting delays or supply chain failures.

Recent activity centers on Florida and the Upper Midwest. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, the response deadline was July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with responses due March 26, 2026 and evaluation weighted heavily toward price competitiveness at 75 percent. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling potential future formal solicitations in that state. The code shows activity across state departments, county governments, and cooperative purchasing vehicles, with emphasis on supply chain compliance and multi-year fixed-pricing arrangements.